Nabriva Therapeutics Receives $5M Payment Under License Agreement with Sinovant Sciences

- September 6th, 2019

Nabriva Therapeutics (NASDAQ:NBRV) has announced that it has received a US$5 million payment under its license agreement with Sinovant Sciences in relation to approval of XENLETA. As quoted in the press release: Sinovant Sciences has an exclusive license to develop and commercialize lefamulin (SNV001) in the Greater China region. Sinovant Science’s application to conduct a … Continued

Nabriva Therapeutics (NASDAQ:NBRV) has announced that it has received a US$5 million payment under its license agreement with Sinovant Sciences in relation to approval of XENLETA.

As quoted in the press release:

Sinovant Sciences has an exclusive license to develop and commercialize lefamulin (SNV001) in the Greater China region. Sinovant Science’s application to conduct a clinical trial of lefamulin (SNV001) in China has been approved by China’s National Medical Products Administration, and the trial is expected to be initiated in the fourth quarter of 2019.

Under its license agreement with Sinovant Sciences, Nabriva is eligible for up to approximately $85 million in additional milestone payments tied to the successful completion of certain regulatory and commercial milestones related to lefamulin for community-acquired bacterial pneumonia (CABP). In addition, Nabriva will be eligible to receive low double-digit royalties on sales, if any, in the Greater China region.

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *